Search research articles
Contact Us
Filters
Showing results (101-110 of 106) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 106 results.
AIDS Research and Human Retroviruses
|
August 1, 2015
A Phase 1 Randomized, Blinded Comparison of the Pharmacokinetics and Colonic Distribution of Three Candidate Rectal Microbicide Formulations of Tenofovir 1% Gel with Simulated Unprotected Sex (CHARM-02)
Hiwot Hiruy, Edward J Fuchs, Mark A Marzinke, et al.
Scientific Reports
|
May 26, 2018
Impact of the griffithsin anti-HIV microbicide and placebo gels on the rectal mucosal proteome and microbiome in non-human primates
Lauren Girard, Kenzie Birse, Johanna B Holm, et al.
Plos One
|
May 6, 2015
A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study)
Ian Mcgowan, Ross D Cranston, Kathryn Duffill, et al.
AIDS Research and Human Retroviruses
|
August 13, 2021
A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study)
Ian M McGowan, Sylvain Chawki, Craig W Hendrix, et al.
Plos One
|
July 31, 2018
Cryopreservation of human mucosal tissues
Sean M Hughes, April L Ferre, Sarah E Yandura, et al.
The Journal of Infectious Diseases
|
November 29, 2023
Tenofovir Douche as HIV Preexposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics (DREAM 01)
Ethel D Weld, Ian McGowan, Peter Anton, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 106) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 106 results.
AIDS Research and Human Retroviruses
|
August 1, 2015
A Phase 1 Randomized, Blinded Comparison of the Pharmacokinetics and Colonic Distribution of Three Candidate Rectal Microbicide Formulations of Tenofovir 1% Gel with Simulated Unprotected Sex (CHARM-02)
Hiwot Hiruy, Edward J Fuchs, Mark A Marzinke, et al.
Scientific Reports
|
May 26, 2018
Impact of the griffithsin anti-HIV microbicide and placebo gels on the rectal mucosal proteome and microbiome in non-human primates
Lauren Girard, Kenzie Birse, Johanna B Holm, et al.
Plos One
|
May 6, 2015
A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study)
Ian Mcgowan, Ross D Cranston, Kathryn Duffill, et al.
AIDS Research and Human Retroviruses
|
August 13, 2021
A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study)
Ian M McGowan, Sylvain Chawki, Craig W Hendrix, et al.
Plos One
|
July 31, 2018
Cryopreservation of human mucosal tissues
Sean M Hughes, April L Ferre, Sarah E Yandura, et al.
The Journal of Infectious Diseases
|
November 29, 2023
Tenofovir Douche as HIV Preexposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics (DREAM 01)
Ethel D Weld, Ian McGowan, Peter Anton, et al.
Page
of 11